Posters
Non-penetrating deep sclerectomy vs trabeculectomy for open angle-glaucoma: retrospective study
Poster Details
First Author: M. Noronha PORTUGAL
Co Author(s): L. Vieira V. Lemos B. Carvalho N. Silva M. Reina T. Gomes
Abstract Details
Purpose:
To compare non-penetrating deep sclerectomy (NPDS) + Esnoper implant with trabeculectomy (TB) + 5-fluorouracil (5-FU) in post-operative reduction of intraocular pressure (IOP), complications and antiglaucoma medication.
Setting:
Centro Hospitalar Lisboa Central Department of Ophthalmology.
Methods:
Retrospective study of 40 eyes (40 patients) with open angle glaucoma (primary open angle glaucoma; pseudoexfoliative and pigmentary), that underwent NPDS+Esnoper (20 eyes) and TB+5-FU (20 eyes). Post-operative results (days 1;7;30;90 and 180) of IOP, complications and antiglaucoma medication were quantified and compared. Absolute success was defined as IOP<18 mmHg without antiglaucoma medication at 180 days time. Relative success was defined as IOP <18 mmHg with or without antiglaucoma medication at 180 days time.
Results:
In the NPDS+Esnoper group mean IOP and antiglaucoma medication (n) were reduced from pre-surgery values of 26,1+/-5,6 mmHg (n= 3,9+/-0,8) to post-surgery values of 8,3+/-2,8 (n=0); 10,1+/-3,5 (n=0); 13,8+/-3,1 (n=0,1+/-0,3); 14,4+/-3,5 (n=0,2+/-0,5) and 13,6+/-2,3 (n=0,3+/-0,6) at 1;7;30;90 and 180 days. In the TB+5-FU group the reductions were from pre-surgery values of 23,0+/-7,4 mmHg (n=3,6+/-0,6) to post-surgery values of 9,2+/-2,3 (n=0); 10,9+/-3,7 (n=0,1+/-0,2); 14,1+/-5,0 (n=0,3+/-0,5); 16,2+/-5,5 (n=0,5+/-0,6) and 14,3+/-3,6 (n=0,6+/-0,7) at 1;7;30;90 and 180 days.
Post-operative complications were 20% in the NPDS+Esnoper group and 30% in the TB+5-FU group. Absolute success rate was 70% for the NPDS+Esnoper group and 55% for the TB+5-FU group (p=0,19). Relative success rate was 95% for the NPDS+Esnoper group and 90% for the TB+5-FU group (p=0,54).
Conclusions:
Our results, while obtained retrospectively, show that NPDS+Esnoper seems to be equally effective as TB+5-FU in the post-operative IOP, complications and antiglaucoma medication reduction.
Financial Disclosure:
NONE